In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with more mild–moderate bleeding but no increase in severe bleeding.